Authors
Latest:
Dr. Quinn on Combinations of Targeted Therapy in RCCDavid I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).
Latest:
Dr. Quinn on Novel Hormonal Therapies in Prostate CancerDavid I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.
Latest:
Dr. Quinn on Current State of Biomarkers in RCCDavid I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.
Latest:
Dr. Quinn on the Future of Treatments for RCCDavid I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on the future of treatments for patients with renal cell carcinoma (RCC).
Latest:
Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLLDavid J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.
Latest:
Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate CancerDavid J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.
Latest:
Dr. Pinato on PD-L1 Testing in HCCDavid J. Pinato, MD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses the role of PD-L1 testing in hepatocellular carcinoma.
Latest:
Dr. Pinato on Guidelines for Toxicity Management in HCCDavid J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).
Latest:
Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin LymphomaDavid J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.
Latest:
HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 TrialsMedical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
Latest:
(Never) A Typical Day in the Life of a Pediatric Hematologist/OncologistThere is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.
Latest:
Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLCDavid L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non­–small cell lung cancer (NSCLC).
Latest:
David Lucas Discusses the Bromodomain Inhibitor OTX015David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.
Latest:
Dr. Euhus on the Rarity of Angiosarcoma of the BreastDavid M. Euhus, MD, director of breast surgery, professor of surgery, Johns Hopkins Medicine, discusses the rarity of angiosarcoma of the breast.
Latest:
Dr. Gershenson on the Results of the MILO Trial in Low-Grade Serous Ovarian CancerDavid M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.
Latest:
Dr. Jackman on Benefits of Liquid Biopsies in Lung CancerDavid M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.
Latest:
Dana-Farber Embraces Pathways in Clinical PracticeDavid M. Jackman, MD, the medical director of Clinical Pathways at Dana-Farber, discusses the benefits of a clinical pathways system.
Latest:
Dr. Kurtz Discusses Using ctDNA to Detect LymphomaDavid M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses using circulating tumor DNA to detect lymphoma.
Latest:
Dr. Nanus on Trials Investigating Immunotherapy in RCCDavid M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses trials investigating immunotherapy regimens for patients with renal cell carcinoma (RCC).
Latest:
Dr. Schuster on Detecting Bone Metastases in Breast CancerDavid Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.
Latest:
Dr Siegel on the Importance of Closing the Gaps in Cancer CareDavid Samuel Dicapua Siegel, MD, discusses the importance of closing the gaps in cancer care and spreading awareness of current treatment inequities in oncology through campaigns such as World Cancer Day.
Latest:
Dr. Maloney on Targets for CAR T-Cell TherapyDavid Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Concluding Thoughts on the DLBCL Treatment LandscapeDLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Latest:
Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate CancerDavid Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.
Latest:
Dr. Mutch on Frontline Treatment in Endometrial CancerDavid Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.
